CLXT News and Press, Calyxt Inc.

Shares of Calyxt, Inc. (NASDAQ: CLXT) traded at a new 52-week high today and are currently trading at $5.4. So far today, approximately 55,181 shares have been exchanged, as compared to an average 30-day volume of 89,248 shares. Calyxt, Inc., a synthetic biology company, engages in delivering...

2023-05-19 16:31:15 ET Calyxt ( NASDAQ: CLXT ) held a special meeting of its stockholders on May 18, where stockholders voted in favor of all proposals, including the issuance of shares of Class A and Class B common stock as part of the proposed merger with Cibus Global. T...

Calyxt Announces Stockholder Approval of Merger With Cibus PR Newswire -- Calyxt Announces 1-for-5 Reverse Stock Split of Common Stock -- ROSEVILLE, Minn. , May 19, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announc...

2023-05-01 16:53:57 ET Calyxt press release ( NASDAQ: CLXT ): Q1 GAAP EPS of -$1.09. Revenue of $0.04M (+33.3% Y/Y). Cash and cash equivalents totaled $2.1 million as of March 31, 2023. Total operating expenses were $4.5 million in the first quarter of 2023 compare...

Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire —P roposed merger with Cibus Global Expected to Close in Q2 2023 — —1-for-10 reverse stock split executed— —Current customer...

Calyxt Completes One-for-Ten Reverse Stock Split PR Newswire ROSEVILLE, Minn. , April 24, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it has completed the previously announced reverse stock split of Calyxt's c...

Calyxt, Inc. Announces Effectiveness of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC PR Newswire ROSEVILLE, Minn. and SAN DIEGO , April 18, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic...

Calyxt Announces Effective Date of Reverse Stock Split PR Newswire ROSEVILLE, Minn. , April 7, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it will proceed with the 1-for-10 reverse stock split previously appro...

2023-03-06 17:05:26 ET Calyxt press release ( NASDAQ: CLXT ): Q4 GAAP EPS of -$0.06. Revenue of $0.04M (-97.9% Y/Y). Cash, cash equivalents, and restricted cash totaled $3.5 million as of December 31, 2022. For further details see: Calyxt GAAP EPS of -$0.06, ...

NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based sy...